US FDA declines to approve Atara Biotherapeutics' cancer therapy
16/01/2025 13:36
Jan 16 (Reuters) - The U.S. Food and Drug Administration
on Thursday declined to approve Atara Biotherapeutics' ATRA.O
cancer therapy, chemically called tabelecleucel.
The company was seeking approval for the therapy to treat
patients with Epstein-Barr virus positive post-transplant
lymphoproliferative disease (EBV+ PTLD).
(Reporting by Kamal Choudhury and Christy Santhosh in
Bengaluru; Editing by Shilpi Majumdar)
((Kamal.Choudhury@thomsonreuters.com))
Recent news on Atara Biotherapeutics
See all newsAtara Biotherapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Atara Biotherapeutics Q2 revenue falls on deferred revenue recognition
Brief: Atara Biotherapeutics Q2 EPS USD -0.32
Atara Biotherapeutics, Inc. expected to post a loss of 31 cents a share - Earnings Preview
Brief: Atara Biotherapeutics - May Offer Up To $79.27 Million In Common Stock As Of May 12, 2026 - SEC Filing